Japanese drugmaker Takeda (TYO: 4502) has signed an option agreement with China’s Ascentage Pharma (HKG: 6855) to enter into an exclusive license agreement for 14 June 2024
Helsinn Group and Chugai Pharma Europe have announced the renewal of their distribution and license agreement for Akynzeo (netupitant-palonosetron) in the UK an 12 June 2024
The Center for Drug Evaluations of the National Medical Products Administration (NMPA) in China has accepted the biologics license application (BLA) for zanidat 11 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.